Literature DB >> 14556969

MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells.

Saho Utsugi-Kobukai1, Haruka Fujimaki, Chie Hotta, Masatoshi Nakazawa, Mutsuhiko Minami.   

Abstract

Exosomes are 50-90 nm vesicles with antigen presenting ability carrying major histocompatibility complex (MHC) class I, class II, abundant co-stimulatory molecules and some tetraspan proteins. Although dendritic cells (DCs) are one of the professional antigen presenting cells capable of presenting exogenous antigens in MHC class I-mediated antigen specific manner (cross-presentation), the cross-presentation ability by exosomes from immature or mature DCs are unknown. Here we show that exosomes released from ovalbumin (OVA) protein-pulsed bone marrow derived dendritic cells (BM-DCs) weakly present the peptide determinants to OVA specific MHC class I-restricted CD8(+) T cell hybridomas. The exosomes secreted by OVA(257-264) peptide- or OVA protein-pulsed mature BM-DCs activated OVA specific MHC class I-restricted T cell hybridomas more efficiently than those from immature BM-DCs. Transporters associated with antigen processing (TAP) deficient mice-derived BM-DCs were also used to examine whether functional TAP activity was required for cross-presentation by exosomes. The exosomes obtained from OVA(257-264) peptide-pulsed BM-DCs derived from TAP(-/-) mice showed a significant antigen presenting ability to OVA specific MHC class I-restricted T cell hybridomas. Altogether, our data indicate that BM-DCs secrete exosomes with weak cross-presentation ability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556969     DOI: 10.1016/s0165-2478(03)00128-7

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  63 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

Review 2.  Exosomes: immune properties and potential clinical implementations.

Authors:  Nathalie Chaput; Clotilde Théry
Journal:  Semin Immunopathol       Date:  2010-12-21       Impact factor: 9.623

3.  Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens.

Authors:  Carolina Obregon; Barbara Rothen-Rutishauser; Stephen Kiama Gitahi; Peter Gehr; Laurent P Nicod
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 4.  Membrane vesicles as conveyors of immune responses.

Authors:  Clotilde Théry; Matias Ostrowski; Elodie Segura
Journal:  Nat Rev Immunol       Date:  2009-06-05       Impact factor: 53.106

5.  Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin.

Authors:  James S Testa; Geraud S Apcher; Joseph D Comber; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

Review 6.  Regulation of immune responses by extracellular vesicles.

Authors:  Paul D Robbins; Adrian E Morelli
Journal:  Nat Rev Immunol       Date:  2014-03       Impact factor: 53.106

Review 7.  Exosomes and other extracellular vesicles in host-pathogen interactions.

Authors:  Jeffrey S Schorey; Yong Cheng; Prachi P Singh; Victoria L Smith
Journal:  EMBO Rep       Date:  2014-12-08       Impact factor: 8.807

Review 8.  Exosomal therapy-a new frontier in regenerative medicine.

Authors:  Sathish Muthu; Asawari Bapat; Rashmi Jain; Naveen Jeyaraman; Madhan Jeyaraman
Journal:  Stem Cell Investig       Date:  2021-04-02

9.  Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth.

Authors:  Takayuki Kogure; Wen-Lang Lin; Irene K Yan; Chiara Braconi; Tushar Patel
Journal:  Hepatology       Date:  2011-07-29       Impact factor: 17.425

Review 10.  Exosomes and immune surveillance of neoplastic lesions: a review.

Authors:  H-G Zhang; X Zhuang; D Sun; Y Liu; X Xiang; W E Grizzle
Journal:  Biotech Histochem       Date:  2012-01-04       Impact factor: 1.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.